Last year, private equity firm Ancor Capital Partners, which Vic Keller serves as a managing partner of, acquired STATinMED Research.
Keller, who is also the founder and CEO of Experience Ventures and is a board member for multiple companies, now serves as STATinMED’s chairman. He says the way STATinMED works is that it “uses customized research methodologies and a diverse set of data sources, along with our team of professionals, to develop strategies.”
STATinMED works alongside clients to provide results for marketability, cost-effectiveness, product development, and economic vitality. Keller says that what sets STATinMED apart as a HEOR company is its “access to broad data sets, a proven analytical structure, and trademarked, advanced algorithms developed in house to produce accurate, optimized results.”
The goal of the company’s research is to form better clinical outcomes, save more money, and create improved value for the pharmaceutical product life cycle.
Dallas Innovates spoke to Keller about STATinMED’s DFW ties and what its plans are for the future.
Why did STATinMED choose to be based in DFW?
Dallas is a great market for STATinMED Research because it is incredibly well-rounded when it comes to top-tier talent, academic institutions, future growth, and forming strategic alliances with other top-notch healthcare companies. We are also proud of STATinMED Research’s unique stake in DFW—to our knowledge, we are the only HEOR company in the region. And our culture is second to none. We think big, have fun and do good—we want seriously smart team members who act with integrity, work with urgency and are accountable and passionate about what they do, while tapping into their curiosity and creativeness.
What are some plans STATinMED Research has for the Dallas-Fort Worth healthcare industry? How are you continuously innovating in this community?
DFW has become a leading healthcare services market with one of the largest pharmaceutical companies, McKesson Corp, relocating their global headquarters to the area. By having our headquarters here in DFW, the region is a transformative opportunity, and this gives us a chance to connect and align with significant partners in the market and focus on our value propositions.
Additionally, our business is based on optimizing data, and DFW is a significant source for real-world data/evidence—health-related information reported and collected in real-world medical settings like patient surveys, clinical trials and observational studies.
What types of companies in the DFW area do you have your eye on to work with?
In addition to all of the healthcare players in our backyard that we can align ourselves with, we have a great appreciation for the highly advanced academic institutions in the area that, among many things, give us a talent pool of the best and brightest when we are looking for data scientists, statisticians, analysts and economists.
What challenges in the Dallas area would your company like to help address?
Healthcare costs and patient access and care continue to be major issues in the industry—issues that STATinMED Research has focused our company and our team’s passions around.
Specifically related to the DFW region, the region is quietly awakening as a biotech hub. With its academic institutions and incubators, it is well positioned to become a new growth market.
What’s next for you guys? Any new projects or concepts you are working on?
STATinMED, the world leader in transformational research, is celebrating its 13th anniversary, and there is a high-level of excitement right now throughout the company. Our reputation for our data resources, proprietary technology and our high-performing work teams is industrywide. We have new dynamic work spaces at both our Dallas and Ann Arbor, Michigan, offices. And our pharmaceutical clients see us as a trusted partner because we deliver the data-driven solutions they are looking for—solutions to some of the world’s biggest health issues.
We are proud of our impressive client roster, and proud of the client relationships we’ve been able to form because our data scientists and analysts are always working on the cutting edge. For example, we are adopting and adapting machine learning and artificial intelligence strategies within our company to increase our competitiveness and deliver faster, better solutions that improve the quality of patient care.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.